Valuation risk isn’t obvious until it’s too late.

Commercialization clarity is a powerful lever you can use before the exit process begins.

Schedule an Exit Readiness Diagnostic to find out ->

Financials may be sound. Growth may be real. Yet valuation discounts appear when buyers struggle to understand how commercial success is created, sustained, and transferred.

Inconsistent positioning, uneven proof, and fragmented go-to-market stories introduce friction late in the process, when timelines are tight and leverage is limited.
These common challenges can appear inside otherwise well-run companies:
Commercial narratives vary widely in roll-ups, even when markets and buyers overlap.
Buyers question durability despite strong revenue and retention metrics.
Exit processes slow as internal teams scramble to align positioning under the pressure of diligence.
CEOs and CMOs describe the business differently in boardrooms and buyer meetings.
Value-creation playbooks work in theory, but fail to prove scalability cleanly post-sale.
The result is avoidable uncertainty introduced late, when clarity is crucial.

This can cost you months and millions.

Why you need a commercialization partner

The objective is speed, clarity, and impact with fewer surprises at exit through:
A repeatable commercialization framework that works across growth teams.
Senior leadership that can operate peer-to-peer with CEOs, boards, and investment teams.
Proof that you have mastered revenue-generation capabilities that compound over time.
Consistency and predictability that reduce execution risk in your GTM plan.
Book my Exit Readiness Diagnostic

Legacy DNA delivers

We operate at the intersection of commercialization, valuation, and leadership alignment. Our work is standardized where it needs to be, automated with AI where it should be, and senior-led where it must be.

You get a growth firm purpose-built for scaling PE-backed healthtech and pharmacy companies with:

  • A systemized approach to commercialization that scales
  • Senior-led engagement rather than just delegated execution
  • Speed to impact measured in weeks and quarters, not planning cycles
  • Human judgment combined with AI acceleration, without credibility shortcuts

Proof in practice

One client doubled revenue and grew gross profit by 202% after implementing this approach.

“Roxie and her team brought consistency across our sales operations and a freshness we needed in marketing. More importantly, they helped our team understand the why and how behind what we were doing — which gave us confidence and momentum. The impact has been tremendous.”
— Dr. Stephen Vogt, Founder & Former CEO of BioPlus Specialty Pharmacy

Need an Exit Readiness Diagnostic?

For operating partners preparing for an exit, the next step is a focused conversation about readiness. 

This is a senior executive-led discussion with one of Legacy DNA’s consultants to surface commercialization risk, alignment gaps, and valuation opportunities across one or more assets. It’s exploratory, educational, and grounded in reality.

Book my Exit Readiness Diagnostic